肠道菌群失调和癌症之间的关键关联是已知的。这里,我们使用全基因组鸟枪测序(WGS)和气相色谱/质谱(GC/MS)进行宏基因组和代谢组学分析,以确定40、45、71、34、50、60和40例患者的共同和不同的分类结构结直肠癌,胃癌,乳腺癌,肺癌,黑色素瘤,淋巴肿瘤和急性髓细胞性白血病(AML),分别,并将数据与性别和年龄匹配的健康对照(HC)的数据进行比较。α-多样性仅在淋巴样肿瘤和AML组及其各自的HC之间存在差异,而β-多样性在所有群体及其HC之间存在差异。在203个独特的物种中,179和24人任职人数不足和过多,分别,在病例组中与HC相比。其中,在所研究的七个组中,肠杆菌的代表性不足,除胃癌组外,厌氧菌在所有人群中的比例都不足,其余五个病例组中有22个物种的代表性不足。除AML组外,所有病例组中肠道微生物组癌指数均显着降低。在测试的短链脂肪酸和氨基酸中,甲酸的相对浓度在每个病例组中都明显高于HC,7种粪杆菌的丰度与大多数氨基酸和甲酸呈负相关,和积极的乙酸水平,丙酸,还有丁酸.我们发现所研究的恶性肿瘤组之间的差异比相似性更多,多样性差异很大,分类学/代谢组学概况,和职能分配。虽然获得的结果可能表明趋势,而不是与不同类型的恶性肿瘤相关的客观差异,新开发的肠道微生物区系癌症指数确实将大多数癌症病例与HC区分开来。我们认为,这些数据是在寻找新的诊断和预测测试以评估癌症患者肠道菌群失调方面向前迈出的有希望的一步。
The key association between gut dysbiosis and cancer is already known. Here, we used whole-genome shotgun sequencing (WGS) and gas chromatography/mass spectrometry (GC/MS) to conduct metagenomic and metabolomic analyses to identify common and distinct taxonomic configurations among 40, 45, 71, 34, 50, 60, and 40 patients with colorectal cancer, stomach cancer, breast cancer, lung cancer, melanoma, lymphoid neoplasms and acute myeloid leukemia (AML), respectively, and compared the data with those from sex- and age-matched healthy controls (HC). α-diversity differed only between the lymphoid neoplasm and AML groups and their respective HC, while β-diversity differed between all groups and their HC. Of 203 unique species, 179 and 24 were under- and over-represented, respectively, in the case groups compared with HC. Of these, Faecalibacillus intestinalis was under-represented in each of the seven groups studied, Anaerostipes hadrus was under-represented in all but the stomach cancer group, and 22 species were under-represented in the remaining five case groups. There was a marked reduction in the gut microbiome cancer index in all case groups except the AML group. Of the short-chain fatty acids and amino acids tested, the relative concentration of formic acid was significantly higher in each of the case groups than in HC, and the abundance of seven species of Faecalibacterium correlated negatively with most amino acids and formic acid, and positively with the levels of acetic, propanoic, and butanoic acid. We found more differences than similarities between the studied malignancy groups, with large variations in diversity, taxonomic/metabolomic profiles, and functional assignments. While the results obtained may demonstrate trends rather than objective differences that correlate with different types of malignancy, the newly developed gut microbiota cancer index did distinguish most of the cancer cases from HC. We believe that these data are a promising step forward in the search for new diagnostic and predictive tests to assess intestinal dysbiosis among cancer patients.